New drug combo targets cancer in brain and spine
NCT ID NCT06724926
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests whether adding the drug azeliragon to radiation therapy is safe for people whose cancer has spread to the lining of the brain and spinal cord. About 21 adults with solid tumors or aggressive brain cancers will receive the combination. The main goal is to find the safest dose and watch for side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH GRADE GLIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
NYU Langone Health
New York, New York, 10016, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug shield nerves from Chemotherapy's side effects?
- Can trained immune cells outsmart brain tumors?
- Can a Tumor's DNA guide better cancer care for kids?
- Could cutting a wider margin around brain tumors extend survival?
- Can a Tumor's genetic blueprint guide better treatment for kids with brain cancer?
- Can a new PET tracer reveal a key cancer target?